These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23025453)

  • 1. Tiotropium inhaler devices: seeking convenience when mortality is at stake?
    Mathioudakis AG; Mathioudakis GA
    J Aerosol Med Pulm Drug Deliv; 2013 Apr; 26(2):120. PubMed ID: 23025453
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm?
    Barnes NC; Jones PW; Davis KJ
    Thorax; 2014 Jun; 69(6):598-9. PubMed ID: 24550061
    [No Abstract]   [Full Text] [Related]  

  • 3. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response.
    Nishimura N
    J Aerosol Med Pulm Drug Deliv; 2013 Apr; 26(2):121. PubMed ID: 23550603
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
    Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of tiotropium bromide (spiriva) in the treatment of patients with chronic obstructive pulmonary disease of varying severity: results of the Russian trial].
    Stepanian IE; Khmel'kova NG; Belin-Atarac B
    Ter Arkh; 2010; 82(10):46-51. PubMed ID: 21341464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
    Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More than just reassurance on tiotropium safety.
    Jenkins CR
    N Engl J Med; 2013 Oct; 369(16):1555-6. PubMed ID: 24131181
    [No Abstract]   [Full Text] [Related]  

  • 11. COPD drugs: the urgent need for innovation.
    Vestbo J; Lange P
    Lancet Respir Med; 2014 Jan; 2(1):14-5. PubMed ID: 24461887
    [No Abstract]   [Full Text] [Related]  

  • 12. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
    Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiotropium and the risk of death in COPD.
    Jenkins CR
    N Engl J Med; 2014 Jan; 370(5):482-3. PubMed ID: 24482820
    [No Abstract]   [Full Text] [Related]  

  • 14. Tiotropium and the risk of death in COPD.
    Verhamme KM; van Blijderveen N; Sturkenboom MC
    N Engl J Med; 2014 Jan; 370(5):481-2. PubMed ID: 24476443
    [No Abstract]   [Full Text] [Related]  

  • 15. Tiotropium and the risk of death in COPD.
    Loke YK; Singh S; Furberg CD
    N Engl J Med; 2014 Jan; 370(5):480-1. PubMed ID: 24476442
    [No Abstract]   [Full Text] [Related]  

  • 16. Tiotropium and the risk of death in COPD.
    Wise RA
    N Engl J Med; 2014 Jan; 370(5):482. PubMed ID: 24476441
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
    Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
    Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium effective in treatment of COPD.
    Kripke C
    Am Fam Physician; 2005 Dec; 72(11):2219-20. PubMed ID: 16345146
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment on tiotropium.
    Tsakok AD
    Respir Med; 2010 Sep; 104(9):1388; author reply 1389. PubMed ID: 20627501
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD.
    Verhamme KM; Sturkenboom MC; Brusselle GG
    Eur Respir J; 2014 Jun; 43(6):1818-9. PubMed ID: 24881063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.